Radionuclide imaging in risk assessment after acute coronary syndromes

J E Udelson, E J Flint

The National Service Framework for coronary artery disease acknowledged a role for myocardial perfusion imaging (MPI) in diagnosis and risk assessment of angina and quoted the cost-effectiveness data from the EMPIRE study. One of its most important effects, however, was to imply increased cardiological management for patients with acute coronary syndromes (ACS). The joint British Cardiac Society and Royal College of Physicians’ guidelines for the management of patients with ACS without persistent ECG ST segment elevation have recommended evaluation of chest pain assessment units based on evidence both from the USA and UK for patients at low cardiac risk. High risk patients, including those with raised troponin, recurrent ischaemic symptoms and/or ST segment changes or adverse stress test results, should have urgent coronary angiography with intention of revascularisation to improve outcomes. In patients with confirmed ACS without recurrent spontaneous symptoms, stress testing provides valuable risk stratification, with pharmacological stress enabling assessment of those who cannot exercise.

This article will review the role of radionuclide techniques across the spectrum of patients with ACS, from those presenting with suspected ACS but without diagnostic initial ECG changes, to the now well defined syndromes of unstable angina (UA)/non-ST segment elevation myocardial infarction (NSTEMI) and ST segment elevation myocardial infarction (STEMI). In these settings, radionuclide imaging techniques have a unique role, strongly supported by an evidence base, as contemporary imaging techniques supply simultaneous information on stress and rest perfusion as well as left ventricular (LV) function. Risk assessment together with appropriate aggressive secondary prevention is particularly helpful in the UK situation of uneven access to revascularisation, allowing for appropriate prioritisation of patients.

IMAGING IN THE CHEST PAIN ASSESSMENT UNIT, EMERGENCY DEPARTMENT, AND MEDICAL ASSESSMENT UNIT

Patients with symptoms suggestive of acute myocardial ischaemia but with non-diagnostic ECG and negative 12 hour enzymes are often subsequently stress tested, mostly with negative results, enabling discharge. Thus, there is a substantial number of unnecessary hospitalisations and unnecessary resource utilisation. The required 16–24 hour observation and testing period may be significantly shortened by MPI. The feasibility of imaging in this situation was originally demonstrated in the Netherlands by Wackers and colleagues using planar thallium-201 techniques. The rapid redistribution characteristics of thallium-201, its limited acute availability, and the need for portable camera systems made widespread use impractical. Many of these impediments to application of imaging in this setting were overcome by the introduction of the technetium 99m (Tc 99m) based agents, sestamibi and tetrofosmin. With their relative lack of redistribution, images may be acquired 45–60 minutes after injection, and reflect myocardial blood flow at the time of injection in the chest pain assessment unit (CPAU). High quality single photon emission computed tomographic (SPECT) imaging may then be undertaken in the nuclear medicine department.

Relationship of imaging results and outcomes

There is now a substantial body of literature evaluating rest SPECT perfusion imaging in the emergency setting. Bilodeau and colleagues performed rest SPECT sestamibi imaging in patients already hospitalised for suspected UA, injecting them with tracer at the time of an episode of spontaneous chest pain while also recording an ECG. The sensitivity of the SPECT sestamibi images for determining the presence of a severe coronary stenosis on subsequent angiography was 95%, while the sensitivity of ECG was only 35%. In patients with acute myocardial infarction (MI), a perfusion defect involving as much as 20% of the left ventricle can exist on acute rest sestamibi imaging in the presence of a normal or non-diagnostic ECG. Despite the presence of resting wall motion abnormalities on echocardiography being less sensitive than resting perfusion defects in the diagnosis of ACS, the lower availability of emergency MPI in most European countries may result in the suboptimal, pragmatic use of ultrasound. Varretto and colleagues first reported from Italy that over 18 months follow up in patients with suspected ACS but a normal resting SPECT sestamibi study in the emergency department (ED), there were no untoward cardiac events. A high negative predictive value for ruling out MI has equalled or exceeded 99% in all published series. Patients with positive results have a substantially higher risk of untoward cardiac events during the index hospitalisation as well as during follow up (figs 1 and 2). Such data suggest that MPI provides important information to assist triage decisions (admit or not admit) in the ED. Where cases of negative resting MPI arise, it is important to follow up with stress testing, secondarily performed to assess or discard the diagnosis of coronary artery disease.

Comparison with enzymatic and biomarkers of ACS

There is an important distinction between the information provided by perfusion imaging and that from biomarker enzyme analysis of myonecrosis. Perfusion imaging data should be abnormal almost immediately after an abnormality in myocardial blood flow is established, while markers may require up to 12–18 hours after symptom onset for optimal sensitivity. Moreover, MPI data should theoretically be abnormal whenever myocardial blood flow is abnormal (that is in both UA and acute MI), whereas biomarkers are positive in virtually all patients with acute MI, but only approximately angioplasty, STEMI, ST segment elevation myocardial infarction; SPECT, single photon emission computed tomographic; Tc 99m, technetium 99m; UA, unstable angina
30–35% of those with a clinical syndrome of UA. Consistent with these concepts, Kontos and colleagues found SPECT sestamibi performed in the ED 92% sensitive for detecting acute MI, while initial cardiac troponin I values drawn at the same time had a sensitivity of only 39%. Subsequently, the maximum troponin I over the first 24 hours had sensitivity similar to that of the acute rest sestamibi imaging, but at a distinctly later time point. Thus, acute MPI has the potential to identify ACS much earlier in their evolution than enzyme markers. Moreover, SPECT perfusion imaging data have been shown to provide incremental risk stratification value for predicting unfavourable cardiac events (fig 3).
appropriately discharge the patient from the ED. Discharge from the ED was observed irrespective of age, sex, and scan strategy. The benefit of more appropriate direct utilisation using an MPI guided strategy included a reduction in risk of unnecessary admissions of patients who had chest pain and MPI. The ERASE chest pain trial randomised 2475 patients with symptoms suggestive of ACS presenting to a diverse group of hospital EDs to a usual evaluation strategy or a strategy including supplementary information from acute rest SPECT, stentibami imaging. Imaging results were immediately incorporated into the triage decision in the scan strategy group. There was a highly significant 20% relative reduction in risk of unnecessary admissions of patients ultimately found not to have an acute ischaemic syndrome (n = 2127, OR 0.68, p < 0.001) in those randomised to the scan strategy. The benefit of more appropriate direct discharge from the ED was observed irrespective of age, sex, risk factors, or relevant imaging experience. In a multivariate analysis, the imaging data were among the most powerful factors associated with the decision to appropriately discharge the patient from the ED.

Randomised trials involving ED patients with acute chest pain and MPI

Stowers and colleagues evaluated 46 patients presenting to the ED with ongoing chest pain and a non-diagnostic ECG before acute MPI. The patients who were randomly assigned to a perfusion imaging guided strategy compared to a conventional strategy incurred costs of $1843 less, with shorter median hospital stay and shorter median intensive care stay, and fewer cardiac catheterisations, but no difference in outcome at 30 days. These data suggest that similar outcomes could be achieved with lower resource utilisation using an MPI guided strategy.

The ERASE chest pain trial randomised 2475 patients with symptoms suggestive of ACS presenting to a diverse group of hospital EDs to a usual evaluation strategy or a strategy including supplementary information from acute rest SPECT, stentibami imaging. Imaging results were immediately incorporated into the triage decision in the scan strategy group. There was a highly significant 20% relative reduction in risk of unnecessary admissions of patients ultimately found not to have an acute ischaemic syndrome (n = 2127, OR 0.68, p < 0.001) in those randomised to the scan strategy. The benefit of more appropriate direct discharge from the ED was observed irrespective of age, sex, risk factors, or relevant imaging experience. In a multivariate analysis, the imaging data were among the most powerful factors associated with the decision to appropriately discharge the patient from the ED.

Thus, the evidence from this strategy controlled, randomised trials suggests that incorporating high quality MPI can improve triage decisions in the ED among patients with suspected ACS, but no definitive ECG changes of acute ischaemia or infarction.

Application of MPI and interpretation in suspected acute ischaemia patients

Patients who report to the ED with symptoms consistent with an ACS and an ECG diagnostic for acute ischaemia or infarction do not benefit from acute imaging, and are triaged based on the presence of ST elevation or ST depression into appropriate therapy algorithms. Ideal patients for imaging are those with non-diagnostic or normal ECGs and symptoms suspicious for acute ischaemia, with no prior history of MI or significant Q waves on the ECG. The latter patients will often have a perfusion defect representative of the old infarction, and thus the data will not be as helpful for discrimination of a new acute ischaemic syndrome.

In the UK, the impetus to develop CPAUs in an emergency admission area is supported in the fifth joint report on provision of cardiac services. In addition to the data on negative predictive value and the favourable impact of MPI on use of resources and clinical decision making, the evidence from Ziffer and colleagues of a SPECT imaging based chest pain analysis protocol reducing the missed infarction rate from 1.8% to 0.1% is encouraging.

While the data from the ERASE chest pain trial and other studies provide compelling evidence for incorporation of acute SPECT MPI into ED evaluation strategies for patients with suspected acute ischaemia, future studies will refine the patient population likely to benefit most from such a procedure. Such patients are likely to have certain clinical characteristics, which may on a larger scale be identified by ECG predictive instruments, for example, in which the pre-test probability of acute ischaemia is so low that imaging is not beneficial. A future direction in imaging might find a potential use of new compounds which can trace hypoxic myocardium. The optimal combination of imaging data, enzyme data and stress testing, and the temporal distribution of such testing also need to be better defined. However, given the very high rate of admission for observation or evaluation from the ED of such patients, the incorporation of MPI has the potential to reduce unnecessary hospitalisations significantly, with potential associated cost savings.

Assessment of patients with NSTEMI/UA

While there is general agreement that patients with high risk clinical characteristics (recurrent in-hospital ischaemic symptoms) in the clinical setting of UA should undergo direct and prompt catheterisation, there is less clear consensus regarding patients with intermediate or low clinical risk as originally defined by the US Agency for Health Care and Policy Research guidelines, including those with medically stabilised UA after initial evidence based therapies. In such patient groups MPI has been shown to identify a low risk outcome group, suggesting that such patients can be managed conservatively without catheterisation (fig 4), while patients with significant demonstrable inducible ischaemia are at high risk, and are therefore selected for intervention (fig 5). The American Heart Association/American College of Cardiology guidelines on cardiac radionuclide imaging considers the use of stress MPI for detecting residual ischaemia and the use of radionuclide angiography to assess LV function in this syndrome as class I indications.

Debate has centred over whether outcomes in all patients with UA/NSTEMI are improved with an early invasive strategy (referral to catheterisation and revascularisation based on anatomic findings at angiography) versus an early conservative strategy (stress testing with referral to catheterisation based on the extent of ischaemia by imaging or on the basis of spontaneous ischaemia). The evidence from several randomised trials is inconsistent on this point, likely reflecting important differences between the studies in patient populations and design features. Strategies using catheterisation in the majority of ACS patients, most often between 4–48 hours after presentation, do not reflect the reality of UK practice where a conservative strategy covers most cases.

Four major clinical trials have now compared outcomes for these two strategies, and based on the results available at the time, the 2000 American College of Cardiology/American Heart Association guidelines assigned both early invasive and early conservative strategies a class I indication. A recent economic analysis of the VANQWISH study found that the conservative strategy is preferable on both clinical (worse survival at 1 year of invasive strategy patients) and economic
grounds. The FRISC-II study suggested benefit for an invasive approach. However, the early conservative strategy group could only be sent to angiography for potential intervention given a stress test with a very strongly positive result, far more strongly positive than is usually considered as a basis for catheterisation referral (at least in the USA). Thus, the early conservative arm in the FRISC-II trial was likely enriched with high risk patients who may well have benefited from revascularisation, providing an advantage to the early invasive randomisation group. In this regard, a recent analysis using the FRISC-II stress test crossover criteria applied to the VANQWISH population found a significant population with high risk coronary angiographic features who would not have been sent for catheterisation had the FRISC-II criteria been applied in that study.

The TACTICS-TIMI-18 trial, in which patients with symptoms of ACS and supportive ECG changes received the platelet inhibitor tirofiban and were randomised to an early invasive or an early conservative strategy, found outcomes favouring the invasive strategy. The absolute benefit was relatively small (reduction of 2 per 1000 deaths and 20 per 1000 non-fatal infarctions), and appeared driven by the clinically higher risk patient subset—that is, the subgroup with elevated troponins and other high risk markers. The VANQWISH and TACTICS-TIMI-18 studies found similar trends in costs: significantly higher initial hospitalisation costs for early invasive therapy and a partial 50% recoup of these costs in follow up.

For patients with UA/NSTEMI, a recent meta-analysis has suggested no clear superiority of early revascularisation in ACS. Such data suggest that a conservative management strategy, in which stabilised patients are risk stratified by stress MPI, offers similar outcomes with fewer invasive procedures. This concept is relevant for UK practice even in the setting of troponin assisted confirmation of ACS and the complexity introduced by the redefinition of MI suggested by the joint European Society of Cardiology/American College of Cardiology committee statement. Given the absence of a clear indication to proceed with an aggressive interventional strategy in all patients with ACS, the principles of assessing LV function and reversible ischaemia to guide management strategy remain powerful.

Thus, the use of MPI following ACS on current evidence as the important decision driving component of the early conservative strategy may therefore reduce the trend towards diminishing marginal returns with invasive management. A recent retrospective analysis of the TIMI-III-B data has shown that by using a simple clinical score (based on age, creatine kinase myocardial band (CK-MB), history of accelerated angina and ST depression on the ECG), over half

Figure 4 Data supporting the use of MPI as the decision point in a conservative management strategy in patients with non-ST segment elevation ACS. The predictive value of stress MPI and stress electrocardiography (stress ECG) is shown in patients studied after initial stabilisation of UA with medical therapy. This figure summarises the results of three studies in which the incidence of cardiac death or non-fatal MI were assessed as end points (% CD/M on y axis) during follow up after stabilisation of UA. The presence of reversible perfusion defects reflective of ischaemia (positive stress MPI) was strongly predictive of cardiac events in this setting; the absence of inducible ischaemia on MPI (negative stress MPI) identifies a low risk group suggesting that such patients can be managed conservatively. Data are less consistent on the use of exercise electrocardiography in this setting. Adapted from Brown.

Figure 5 Positive MPI study in a patient with medically stabilised UA. After presentation, symptoms were controlled with initial medical therapy, and stress MPI was performed. There is evidence of an inferobasal infarct (arrowhead) but the large extent of inducible ischaemia involving the inferoapical and lateral walls (arrows) suggests high risk for future events, and the patient was subsequently referred for catheterisation.
of the population could be classified as low risk. These patients demonstrated no benefit in prevention of death or MI up to one year after the early invasive strategy, suggesting that for such patients, a conservative strategy incorporating stress MPI would help to optimally select the subgroup most likely to benefit from intervention, as well as those not likely to benefit. In TACTICS-TIMI-18, the troponin positive subgroup, constituting 60% of the total population, had a larger reduction in death or MI with the early invasive strategy. Therefore TACTICS type patients without elevation of troponin or high TIMI risk score may be optimally managed by a more conservative approach with risk stratification by using imaging techniques. The UK guidelines include the conservative strategy even for patients with an abnormal troponin, providing symptoms have settled for 48 hours and there are no other high risk features.

Importance of LV function assessment in patients with UA

Most of the randomised trials of invasive versus conservative management strategies in UA/NSTEMI have not clearly taken into account the presence or magnitude of LV dysfunction, the importance of which should not be lost in the debate on the optimal strategy. In most patients with UA/NSTEMI, LV function is usually preserved, and is therefore not as powerful an incremental discriminator of subsequent risk. In a randomised trial of medical versus revascularisation therapy in UA, the degree of LV dysfunction played an important role in defining an advantage of surgical therapy among those whose baseline resting LV ejection fraction was < 50%. In the contemporary practice of radionuclide imaging, referral for stress perfusion imaging will almost always result in the provision of simultaneously derived information on LV function, using the now widely available gated SPECT techniques. This information will more fully inform the decision process than information on perfusion alone.

Future directions

A potential future approach to risk stratification in patients with suspected ACS or UA/NSTEMI involves the use of imaging fatty acid metabolism. Evidence suggests that following a regional ischaemic insult, abnormalities in fatty acid metabolism resulting from ischaemia may persist long after perfusion has returned to normal, demonstrating the property of ischaemic memory. Imaging fatty acid metabolism may therefore allow assessment of the recent presence and extent of ischaemia even well after symptom resolution, potentially without the need for stress.

In a recent study, Kawai and colleagues used a radiolabelled fatty acid analogue, β-methyl-iodophenyl pentadecanoic acid (BMIPP) with SPECT imaging, performed 1–5 days after presentation in 111 patients with suspected ACS. The BMIPP images showed greater sensitivity than rest perfusion imaging within 24 hours in identifying the presence and site of the culprit coronary stenosis or spasm (74 vs 38% respectively, p < 0.05) at similar high specificity (fig 6). Future studies will determine whether such a technique can help guide management in such patients.

ASSESSMENT OF PATIENTS WITH STEMI

Clinical variables such as recurrent ischaemia, heart failure, and non-acute arrhythmias during the hospitalisation for acute STEMI identify a patient subgroup at high risk in which there is general agreement that early catheterisation and intervention is indicated. However, the majority of patients surviving the initial acute infarction period will have a relatively stable and uncomplicated course. In these patients, current guidelines generally recommend non-invasive risk stratification before hospital discharge.

Assessment of myocardial perfusion and inducible ischaemia after acute STEMI

A large body of literature documents three major determinants of natural history risk following an index acute infarction. These factors include residual resting LV function, the extent of ischaemic, jeopardised myocardium, and the susceptibility to ventricular arrhythmias. Thus, measures of LV function and the extent of inducible ischaemia would be expected to provide important prognostic information in the aftermath of acute MI, with the potential to guide management decisions regarding catheterisation and subsequent intervention. Gated SPECT imaging, on the basis of its comprehensive ability to provide all of this important information, has the potential to be the single most important test in the stable patient following a STEMI.

One of the earliest studies to examine the relation of perfusion imaging data to outcomes in stable patients following MI was published by Gibson and colleagues in 1983. In this report, thallium 201 scintigraphic data contained the most robust information on stratifying risk, in that a low risk thallium 201 image (defined as one thallium defect, no reversible defects or no lung uptake) was associated with a very low risk natural history outcome, with only 6% of patients suffering cardiac events during a three year follow up. In contrast, patients with a high risk test (defined as no ST depression or exercise induced angina) had a 25% incidence of cardiac events on follow up, while patients with a low risk coronary angiogram (defined as 0–1 vessel disease) had a 22% incidence of subsequent events.

As data on the value of exercise perfusion scintigraphy was emerging throughout the early to mid 1980s, a simultaneous line of investigation was being reported on the value of pharmacologic stress imaging in the same clinical setting. An important proportion of patients following uncomplicated MI are not able to exercise even to a submaximal workload. These patients are generally at higher risk of subsequent cardiac death or MI compared to the cohort able to exercise. Leppo and colleagues reported that the presence of redistribution (ischaemia) on a dipyridamole thallium 201 scan was the only significant predictor of important cardiac events on multivariate analysis, while the absence of redistribution defects identified a low risk cohort. Subsequent reports confirmed these findings.

Many studies in the thrombolytic era have reported similar favourable results regarding the relation of stress induced scintigraphic ischaemia to outcomes, as those reported in the pre-thrombolytic era. Travin and colleagues used Tc 99m
sestamibi SPECT imaging after MI in 134 consecutive patients within 14 days of an uncomplicated MI and found that the extent of ischaemia on the SPECT sestamibi scan was the only significant correlate of a future cardiac event on Cox regression analysis (fig 7). Among the subgroup who had received thrombolytic therapy (40%), the extent of sestamibi SPECT ischaemia remained a strong correlate of a cardiac event. Mahmarian and colleagues46 found that the quantified extent of ischaemia on adenosine SPECT thallium 201 imaging was an important predictor of post-MI cardiac events by Cox regression analysis.

These data are likely representative of the contemporary management of MI in large populations and suggest that there is an important role for scintigraphic imaging in the current era. In a study also likely to be reflective of current practice in the UK, Basu and colleagues studied 100 patients after uncomplicated MI who had received thrombolytic therapy and were admitted to the critical care unit at Northwick Park Hospital, and subsequently underwent stress thallium 201 imaging.47 When information regarding ischaemia was obtained by the use of stress and nitrate enhanced rest thallium 201 imaging, reversible ischaemic defects were detected in 68 patients, of whom 49% had events, while of 32 without evidence of inducible ischaemia, only 13% had subsequent cardiac events (hazard ratio 8.1, 95% CI 2.7 to 23.8; p < 0.001).

Clinical trials incorporating results of stress testing following MI

The true power of a predictive test is best demonstrated, insofar as it can be used for clinical decision making, to improve outcomes not only predict outcomes. In this regard, several studies have been reported in which the presence of inducible ischaemia following MI was used to guide clinical decisions.

The TIMI-II trial48 randomised 3339 patients, who received intravenous tissue-type plasminogen (t-PA) for acute MI, to either an invasive strategy (cardiac catheterisation at 18–48 hours after infarction with subsequent angioplasty or bypass surgery depending on anatomy), or a conservative arm in which cardiac catheterisation was performed only in response to spontaneous or inducible ischaemia (by stress radionuclide ventriculography). The one year outcome results were similar between the invasive or conservative strategy. The investigators concluded that a non-invasive strategy with pre-discharge stress imaging examining for the presence of inducible ischaemia will be associated with similar outcomes with less need for catheterisation and revascularisation than a direct catheterisation strategy. Cost effectiveness is implied by the similar outcomes associated with fewer catheterised patients.

The absence of scintigraphic ischaemia has also been investigated as to its influence on clinical decision making for intervention after MI. Ellis and colleagues49 reported on 87 patients who had received thrombolytic therapy for acute MI...
and subsequently had a negative functional test for ischaemia in the setting of a residual stenosis of the infarct related artery. The patients were randomised to either medical therapy or to angioplasty of the infarct related artery stenosis. There were no differences between the study groups in the change from rest to exercise ejection fraction or in the resting ejection fraction at the six week end point. Actuarial 12 month infarct-free survival was 98% in the conservative therapy group and 91% in the group randomised to percutaneous coronary intervention (p = 0.07) (fig 8). This trial demonstrates that patients with no evidence of scintigraphic ischaemia within the infarct zone, even in the setting of a residual stenosis of the infarct related artery, derive no benefit from angioplasty of the infarct related artery.

The results of such trials suggest that scintigraphic testing for the presence and extent of myocardial ischaemia in the aftermath of an acute MI can indeed play an important role in clinical decision making regarding the need for and utility of catheterisation and revascularisation, and can also identify a cohort of patients whose outcome will be favourable without catheterisation. With the expectation of wider application of aggressive secondary prevention strategies in the post-MI population, it might be anticipated that the low risk post-MI outcome cohort will continually expand, making their identification before discharge even more compelling.

**Very early post-MI risk stratification**

Pharmacologic stress with adenosine or dipyridamole induces coronary hyperaemia with only minimal increments in oxygen demand, thus is potentially safer to administer very early after MI. This concept, which if feasible would potentially allow identification of high and low risk cohorts earlier in the post-MI recovery phase than standard stress testing, was examined by Brown and colleagues. In this study, 451 patients were randomised to a standard post-MI evaluation strategy, or to a strategy incorporating dipyridamole-sestamibi imaging 2–3 days after uncomplicated MI. The testing was safe, and the imaging information supplied powerful risk stratification data predicting two year outcomes, that more powerfully predicted outcomes than the submaximal stress imaging data. The investigators concluded that, “this technique can allow management decisions to be made earlier with regard to acute MI patients and could have important economic impact if applied widely”.

It may be important to separate patients receiving thrombolytic therapy (for whom the decision for coronary revascularisation performed out of the acute phase will be dependent upon the extent of jeopardised/ischaemic myocardium), and patients treated by primary or rescue PTCA. In the latter patients rest/redistribution MPI may be helpful to predict late functional recovery.

**Studies examining both perfusion imaging and LV function following acute MI**

Large databases have been examined in both the pre- and post-reperfusion era to assess post-MI LV function as a predictor of short and long term outcomes. As post-MI ejection fraction falls, there is a progressive increase in mortality risk. The availability of gated SPECT imaging to simultaneously evaluate myocardial perfusion and LV function at little additional effort and cost, compared to perfusion imaging alone, raises the important question regarding the incremental information provided by combining the analysis of perfusion and function information within one test. As the cost of adding the gated SPECT LV function information is modest once perfusion imaging is performed, the increment of information required for cost effectiveness is similarly modest.

Mahmariand and colleagues studied 146 post-MI patients with assessment of LV function as well as adenosine SPECT thallium tomography, and related findings to cardiac events over an average of 16 months of follow up (fig 8). Knowledge of both the extent of perfusion defect/ischaemia size along with information on LV ejection fraction allowed risk categorisation superior to that provided by either variable alone. These data strongly suggest that measurement of perfusion abnormalities (total defect size and quantitative extent of ischaemia) and LV ejection fraction following MI have complimentary roles, and together are powerful instruments for categorising patient risk in this setting. Given the opportunity to derive these variables simultaneously, gated

---

**Figure 8** In a study by Ellis and colleagues, patients who had received thrombolytic therapy for acute MI who had a residual stenosis of the infarct related artery but no inducible ischaemia in the infarct territory by MPI were randomised to either a strategy of percutaneous transluminal coronary angioplasty (PTCA) of the residual stenosis or a strategy of no PTCA. Shown is a plot of actuarial freedom from cardiac events after randomisation to PTCA (solid line) or medical therapy (dashed line). There is no difference in outcome between the groups. Hence, identification of inducible ischaemia or lack thereof within the infarct zone by perfusion imaging after acute MI and reperfusion therapy can guide management decisions regarding revascularisation strategy. In the absence of any residual infarct zone ischaemia, there appears little benefit from a strategy of revascularisation. From Ellis and colleagues.

**Figure 9** Cox regression models displaying one year post-MI risk for cardiac event according to LV ejection fraction and total LV ischaemia. The diagonal lines are representative of isobars of per cent risk of event. Patient risk for any cardiac event increases as total LV ischaemia increases and LV ejection fraction decreases. LV ejection fraction and scintigraphic results for each of 92 patients who did (solid circles) or did not (open circles) have subsequent cardiac events over entire follow up period are plotted against calculated risk at one year. From Mahmariand and colleagues.
SPECT perfusion imaging should provide a powerful impetus for optimising post-MI risk stratification.

FUTURE DIRECTIONS

Response of ischaemia to medical therapy

Among patients with high risk scintigraphic or clinical signs, only a minority will indeed suffer an important cardiac event during follow up. Therefore in order to prevent an exceptional cardiac event, most, if not all, of these high risk patients undergo intervention. While clinicians accept this trade off, recent intriguing data involving perfusion imaging suggest that the response of scintigraphic ischaemia to medical therapy may identify the subgroup within the high risk cohort who will suffer a cardiac event, and would therefore benefit most from an invasive strategy.

Dakik and colleagues studied 44 stable MI survivors with adenosine SPECT thallium 201 imaging approximately four days after acute MI, who had large total and ischaemic perfusion defect size (that is, a high risk result). Patients were randomised to either intensive medical therapy or coronary angioplasty. The extent of ischaemia was similarly reduced on medical therapy compared to the patients undergoing angioplasty on a follow up scan six weeks later. Event-free survival was significantly related to the reduction in perfusion defect size, independent of the intervention. These data would suggest that the proportion of patients within the high risk cohort who are destined to remain stable might be identified on the basis of the response of scintigraphic ischaemia to medical therapy. These important and encouraging pilot data are now being examined in a large randomised multi-centre trial.

Wall motion and volume

The use of low dose dobutamine gated SPECT in ischaemic wall motion analysis, and gated SPECT evaluation of LV volume measurement demonstrating incremental prognostic value are important future directions for development.
Assessment of cardiac sympathetic innervation

An emerging area of scintigraphic risk stratification in the post-MI setting involves the use of I-123 metaiodobenzylguanidine (MIBG) imaging of cardiac sympathetic innervation. In the post-MI setting, several studies have shown that the territory of abnormal MIBG uptake, corresponding to sympathetic denervation, may often exceed the final infarct size, and that such patients may be at higher risk for subsequent ventricular arrhythmias. Matsunari and colleagues, using SPECT Tc 99m sestamibi imaging of infarct risk area and final infarct size, as well as MIBG imaging in acute MI patients, demonstrated that the territory of sympathetic denervation corresponded more closely to the initial MI risk area than the final infarct size (fig 10). Should such findings in the contemporary therapeutic era prove prognostic for late post-MI outcomes, as suggested by earlier studies, MIBG imaging may prove useful in selecting post-MI patients who may optimally benefit from implantable defibrillators.

Annexin imaging

An exciting new potential approach to evaluating post-MI patients using non-invasive imaging is the in vivo visualisation of apoptosis or programmed cell death. Investigations are now underway in humans using Tc 99m labelled annexin-V, which localises to apoptotic cells. Hofstra and colleagues found positive uptake of this agent in six out of seven post-MI patients, localised to areas of resting perfusion defects (fig 11). Should these data be confirmed in larger studies, it will herald the onset of the ability to non-invasively track this process in clinical syndromes, and potentially study therapeutic approaches to attenuate the unfavourable pathophysiology.

CONCLUSIONS

Radionuclide imaging can supply critically important prognostic information in the setting of ACS, whether in suspected ACS without obvious ischaemic ECG changes in the CPAU or ED, or in the clinical setting of NSTE-ACS/UA, or STEMI. The high negative predictive value in ED patients with chest pain and non-diagnostic ECG changes can drive triage decisions regarding admission or discharge. Among ACS patients who have stabilised clinically but have a high risk substrate identified by imaging, outcomes may be improved by revascularisation. The absence of ischaemia on perfusion imaging in the aftermath of a clear ACS suggests that a conservative management strategy, including aggressive secondary prevention medical measures, is appropriate. Ongoing research in this area involves new tracers of metabolic and pathophysiological processes that may allow more specifically directed therapy after ACS.

Authors’ affiliations

J E Udelson, Division of Cardiology, Tufts-New England Medical Center Hospitals, Tufts University School of Medicine, Boston, Massachusetts, USA
E J Flint, Dudley Group of Hospitals, Wardsley Hospital, Steadbridge, West Midlands, UK

Correspondence to: Dr Jane Flint, Dudley Group of Hospitals, Wardsley Hospital, Steadbridge, West Midlands, UK; jane.flint@duddleygoh-tr.nhs.uk

REFERENCES

Radionuclide imaging in risk assessment after ACS


34 Dargie H. Myocardial infarction: redefined or reinvented? Heart 2002;88:1–3.


Radionuclide imaging in risk assessment after acute coronary syndromes

J E Udelson and E J Flint

*Heart* 2004 90: v16-v25
doi: 10.1136/hrt.2004.041194

Updated information and services can be found at:
http://heart.bmj.com/content/90/suppl_5/v16

*These include:*

**References**
This article cites 53 articles, 22 of which you can access for free at:
http://heart.bmj.com/content/90/suppl_5/v16#BIBL

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Topic Collections**
Articles on similar topics can be found in the following collections

- Drugs: cardiovascular system (8842)
- Acute coronary syndromes (2742)
- Clinical diagnostic tests (4779)
- Interventional cardiology (2933)
- Percutaneous intervention (964)

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/